Clinical efficacy and safety study of Aripiprazole combined with Mirtazapine in the treatment of patients with somatoform disorders
CAI Wen-ting1 LAI Yan1 LIAO Mei-rong2 LAI Zhong-hong1 XIAO Feng1
1.Male Ward,Department of Early Intervention,the Third People′s Hospital of Ganzhou City
2.Outpatient Clinic,the Third People′s Hospital of Ganzhou City
Abstract：Objective To investigate the effect of Aripiprazole combined with Mirtazapine in the treatment of somatoform disorders.Methods A total of 100 patients with somatoform disorders admitted to the Third People′s Hospital of Ganzhou City from June 2019 to March 2020 were selected as the research subjects.By drawing lots method,they were divided into a control group and an observation group,with 50 cases in each group.In the control group,Mirtazapine was used,and in the observation group,Aripiprazole combined with Mirtazapine was added.The disease condition,psychological state,and clinical side effect before and after treatment in the two groups were compared.Results There were no statistically significant differences between the two groups in the severity of disease and psychological state before treatment (P＞0.05).The self-rating symptom scale (SCL-90) score of the observation group eight weeks after treatment was (74.32±8.24) points,lower than that of the control group of (100.24±10.15) points,and the difference was statistically significant (P＜0.05).The Hamilton anxiety scale (HAMA) score eight weeks after treatment was (13.52±1.26) points in the observation group,lower than that in the control group of (20.12±1.45) points,and the Hamilton depression scale(HAMD) score was (14.08±1.32) points,lower than that in the control group of (21.27±1.60) points,the differences were statistically significant (P＜0.05).Thereatment emergent symptom scale (TESS) scores of patients in the observation group at 2,8 weeks after treatment ([30.12±1.24],[12.32±1.27]points) were lower than those of the control group([48.27±2.15],[25.48±2.65]points),the differences were statistically significant (P＜0.05).Conclusion The combination of Aripiprazole and Mirtazapine for patients with somatoform disorders can reduce the severity of the disease,alleviate negative emotions,reduce the adverse effect after medication,and has high promotion and application value.
蔡文婷；赖燕；廖梅蓉；赖忠红；肖峰. 阿立派唑联合米氮平治疗躯体形式障碍患者的临床疗效及安全性研究[J]. 中国当代医药, 2020, 27(35): 82-85.
CAI Wen-ting；LAI Yan；LIAO Mei-rong；LAI Zhong-hong；XIAO Feng. Clinical efficacy and safety study of Aripiprazole combined with Mirtazapine in the treatment of patients with somatoform disorders. 中国当代医药, 2020, 27(35): 82-85.
京公网安备 11010502046607号